Sellas Life Sciences Group Inc Cash Flow Conversion Efficiency
Sellas Life Sciences Group Inc cash flow conversion efficiency. Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has a cash flow conversion efficiency ratio of -0.055x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.59 Million) by net assets ($137.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sellas Life Sciences Group Inc (SLS) total market value for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Sellas Life Sciences Group Inc (2007–2025)
Cash flow conversion efficiency of Sellas Life Sciences Group Inc from 2007 to 2025. This chart illustrates how Sellas Life Sciences Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Sellas Life Sciences Group Inc for real-time trading data and today's change.
Sellas Life Sciences Group Inc Cash Flow Conversion Ratio Explained
Sellas Life Sciences Group Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sellas Life Sciences Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their cash flow conversion efficiency. Review Sellas Life Sciences Group Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Westshore Terminals Investment Corp
TO:WTE
|
0.150x |
|
Cyfrowy Polsat SA
WAR:CPS
|
0.052x |
|
Centrus Energy Corp.
NYSE MKT:LEU
|
-0.063x |
|
Henan Yuneng Holdings Co Ltd
SHE:001896
|
0.379x |
|
Evergreen Aviation Tech Corp
TW:2645
|
0.059x |
|
Minerals Technologies Inc
NYSE:MTX
|
0.040x |
|
Whirlpool Corporation
NYSE:WHR
|
-0.031x |
|
Chang Wah Technology Co Ltd
TWO:6548
|
0.009x |
Annual Cash Flow Conversion Efficiency for Sellas Life Sciences Group Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sellas Life Sciences Group Inc from 2007 to 2025. Also see Sellas Life Sciences Group Inc assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.87 Million | $-28.39 Million | -0.401x | +89.29% |
| 2024-12-31 | $9.46 Million | $-35.40 Million | -3.740x | -194.98% |
| 2023-12-31 | $-7.98 Million | $-31.41 Million | 3.938x | +180.24% |
| 2022-12-31 | $4.85 Million | $-23.81 Million | -4.908x | -283.78% |
| 2021-12-31 | $20.35 Million | $-26.02 Million | -1.279x | -243.27% |
| 2020-12-31 | $27.96 Million | $-10.42 Million | -0.373x | +87.13% |
| 2019-12-31 | $6.09 Million | $-17.64 Million | -2.896x | +50.08% |
| 2018-12-31 | $5.25 Million | $-30.42 Million | -5.800x | -9.26% |
| 2017-12-31 | $2.07 Million | $-10.99 Million | -5.309x | -238.71% |
| 2016-12-31 | $28.66 Million | $-44.91 Million | -1.567x | +56.02% |
| 2015-12-31 | $13.51 Million | $-48.16 Million | -3.564x | -208.10% |
| 2014-12-31 | $37.06 Million | $-42.87 Million | -1.157x | +76.45% |
| 2013-12-31 | $5.89 Million | $-28.91 Million | -4.911x | -550.28% |
| 2012-12-31 | $27.76 Million | $-20.96 Million | -0.755x | +47.93% |
| 2011-12-31 | $10.11 Million | $-14.67 Million | -1.451x | +65.63% |
| 2010-12-31 | $2.43 Million | $-10.26 Million | -4.221x | +73.42% |
| 2009-12-31 | $741.00K | $-11.77 Million | -15.883x | -1410.61% |
| 2008-12-31 | $8.97 Million | $-9.43 Million | -1.051x | -88.18% |
| 2007-12-31 | $10.82 Million | $-6.05 Million | -0.559x | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more